Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
antineoplastic agent |
| gptkbp:approvalYear |
2017
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
P01CA02
|
| gptkbp:CASNumber |
71610-00-9
|
| gptkbp:chemicalFormula |
C12H12N4O3
|
| gptkbp:contraindication |
severe liver disease
hypersensitivity to benznidazole |
| gptkbp:discoveredBy |
gptkb:Roche
|
| gptkbp:eliminationHalfLife |
12 hours
|
| gptkbp:excretion |
urine
|
| https://www.w3.org/2000/01/rdf-schema#label |
benznidazole
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits DNA synthesis in Trypanosoma cruzi
|
| gptkbp:metabolism |
hepatic
|
| gptkbp:molecularWeight |
284.25 g/mol
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
peripheral neuropathy rash |
| gptkbp:synonym |
gptkb:Benznidazol
Radanil |
| gptkbp:usedFor |
gptkb:Chagas_disease
|
| gptkbp:WHOModelListOfEssentialMedicines |
included
|
| gptkbp:bfsParent |
gptkb:American_trypanosomiasis
gptkb:Trypanosoma_cruzi gptkb:Chagas_disease gptkb:Trypanosoma |
| gptkbp:bfsLayer |
6
|